68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

计划入组 300 人 · 首次发布于 2023 年 12 月 4 日

Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

计划入组 80 人 · 首次发布于 2024 年 2 月 13 日

Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours

计划入组 156 人 · 首次发布于 2016 年 6 月 2 日

Alpha-lactalbumin-oleic acid (Azanta)

Lutetium Lu 177 dotatate(Lutathera)

C₆₅H₈₇LuN₁₄O₁₉S₂

Lanreotide(Somatuline)

C₅₄H₆₉N₁₁O₁₀S₂ · Rx

Crinetics

United States

The Nemours Foundation

United States

NEMOURS CHILDREN'S CLINIC

United States

Lantheus gains FDA approval for Bravnetsa in GEP-NET

ITM-11 Demonstrates Superior Progression-Free Survival Compared to Everolimus in GEP-NETs

XTR008 Achieves Dramatic Progression-Free Survival Benefit in Advanced Gastroenteropancreatic Neuroendocrine Tumors